Illumina acquires Fluent BioSciences to bolster single-cell analysis capabilities

USA — Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has acquired Fluent BioSciences, a pioneering developer of advanced single-cell technologies.

This acquisition marks Illumina’s strategic move to bolster its capabilities in single-cell analysis, a rapidly growing field in genomics.

Following the acquisition, the entire Fluent BioSciences team will integrate into Illumina, bringing with them their innovative single-cell technology, notably their latest advancement, PIPseq V.

This technology will be seamlessly integrated into Illumina’s product portfolio, enhancing their offerings in single-cell analysis.

Illumina plans to leverage Fluent’s cutting-edge technology to develop comprehensive end-to-end solutions for single-cell analysis.

This initiative aims to empower researchers with robust tools that streamline discovery processes.

Commenting on the acquisition, Steven Barnard, Illumina’s chief technology officer, noted that the addition of Fluent BioSciences will provide significant new capabilities to its customers in a key growth area and advance its multi-omics growth strategy.

 He emphasized that single-cell research opens doors to new areas of discovery, and Fluent’s innovative, accessible, and flexible single-cell method will accelerate their ability to deliver full multiomics solutions for their customers.

Illumina will remain an open NGS platform and is committed to maintaining and supporting its existing single-cell partnerships.

Barnard highlighted, “Our goal is to continue to develop the sequencing ecosystem and support the best multiomics solutions like single-cell analysis.”

He emphasized the company’s commitment to allowing customers to adopt tools that best suit their research needs.

Fluent’s single-cell analysis technology eliminates the need for complex, expensive instrumentation and microfluidic consumables.

This novel approach removes many barriers and limitations of current methods, making single-cell analysis accessible to a broader customer base.

Fluent’s latest release, PIPseqV, delivers exceptional performance, catalyzing new experiments enabled by the ability to perform the assay at the point of sample collection.

It has the capability to detect cell types often missed with current methods and offers scalability, capable of processing a range from 100 cells up to 1 million.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook